Ameritas Investment Partners’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,067
| Closed | -$40.1K | – | 3117 |
|
|
2025
Q4 | $40.1K | Hold |
3,067
| – | – | ﹤0.01% | 2274 |
|
|
2025
Q3 | $22.3K | Sell |
3,067
-1,904
| -38% | -$12.9K | ﹤0.01% | 2607 |
|
|
2025
Q2 | $26.6K | Hold |
4,971
| – | – | ﹤0.01% | 2532 |
|
|
2025
Q1 | $26.5K | Hold |
4,971
| – | – | ﹤0.01% | 2427 |
|
|
2024
Q4 | $44.4K | Hold |
4,971
| – | – | ﹤0.01% | 2256 |
|
|
2024
Q3 | $54.7K | Hold |
4,971
| – | – | ﹤0.01% | 2141 |
|
|
2024
Q2 | $45.2K | Hold |
4,971
| – | – | ﹤0.01% | 2197 |
|
|
2024
Q1 | $70K | Buy |
4,971
+2,861
| +136% | +$35.6K | ﹤0.01% | 1950 |
|
|
2023
Q4 | $16.2K | Hold |
2,110
| – | – | ﹤0.01% | 2682 |
|
|
2023
Q3 | $15.7K | Hold |
2,110
| – | – | ﹤0.01% | 2648 |
|
|
2023
Q2 | $17.6K | Buy |
+2,110
| New | +$24.3K | ﹤0.01% | 2629 |
|
|
2021
Q2 | – | Sell |
-266
| Closed | -$5K | – | 3060 |
|
|
2021
Q1 | $5K | Hold |
266
| – | – | ﹤0.01% | 2995 |
|
|
2020
Q4 | $3K | Hold |
266
| – | – | ﹤0.01% | 3019 |
|
|
2020
Q3 | $10K | Hold |
266
| – | – | ﹤0.01% | 2701 |
|
|
2020
Q2 | $10K | Buy |
+266
| New | +$9.47K | ﹤0.01% | 2698 |
|
Ameritas Investment Partners's ATXS Position: Q1 2026 in Review
Ameritas Investment Partners sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 3,067 shares — an estimated $40.1K sold.
Ameritas Investment Partners first reported a position in ATXS in Q2 2020 and held it in 15 quarters. The position peaked at $70K in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Ameritas Investment Partners reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Ameritas Investment Partners sold 3,067 Astria Therapeutics shares in Q1 2026, an estimated $40.1K.
- Ameritas Investment Partners first reported a position in Astria Therapeutics in Q2 2020 and held it in 15 quarters.
- Ameritas Investment Partners's Astria Therapeutics position peaked at $70K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.